Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.
Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.
A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.
Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.
Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.
Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.
For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.
Codexis, a leader in enzyme engineering, will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York City. The chat is scheduled for December 1, 2022, at 1:30 p.m. ET and will be webcast live, with an archive available for 90 days post-event. Codexis focuses on developing innovative enzymes and biotherapeutics that enhance sustainability in pharmaceuticals and food production, promising significant operational improvements.
Codexis, a leader in enzyme engineering, announced management's participation in three investor conferences. The events are: the Stephens Annual Investment Conference on November 15, 2022, the Stifel 2022 Healthcare Conference on November 16, 2022, and the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022.
Live webcasts of the fireside chats will be available on the company's website, with replays archived for 90 days post-event.
Codexis reported Q3 2022 financial results, revealing total revenues of $34.5 million, down 6% year-over-year. Product revenues decreased by 2% to $28 million, driven by reduced enzyme sales related to Pfizer's PAXLOVID. R&D revenues fell to $6.4 million, while R&D expenses rose to $21.8 million. The company's net loss was $10 million, translating to a loss of $0.15 per share. Codexis reiterated its total revenue guidance for 2022 at $135-$141 million, expecting product revenues of $112-$118 million, alongside a gross margin of 65%-70%. Cash reserves stand at $108.7 million.
Codexis (NASDAQ: CDXS) has appointed Margaret Fitzgerald as Chief Legal Officer and General Counsel. Effective immediately, she will oversee the company’s legal and compliance functions, reporting to President and CEO Dr. Stephen Dilly. Fitzgerald brings over 20 years of experience in the biotechnology sector, previously serving as General Counsel at Allakos, Inc. Her extensive background in legal matters, product development, and compliance is expected to bolster Codexis's strategic growth in enzyme engineering, enhancing its capacity for innovation across core markets.
Codexis, Inc. (Nasdaq: CDXS) will report its Q3 2022 financial results on November 3, 2022, after market close. A conference call and webcast for discussing the results and providing a business update will follow at 4:30 p.m. ET. Participants can access the live webcast via Codexis' Investor Relations website. Codexis specializes in enzyme engineering, with applications in pharmaceuticals, food, and industrial products, aimed at improving sustainability and health outcomes.
Codexis, Inc. (NASDAQ: CDXS) has appointed Kevin Norrett as Chief Operating Officer (COO) to spearhead corporate growth and operational strategies. Norrett, with over 20 years in the biotech sector, including roles at Sierra Oncology and Angion Biomedica, will work with CEO Dr. Stephen Dilly. His appointment aims to strengthen Codexis' leadership in Performance Enzymes and Biotherapeutics, particularly in sustainable manufacturing for life sciences. Norrett expressed enthusiasm for converting Codexis' scientific innovations into commercial outcomes.
Codexis has appointed Dr. Rahul Singhvi to its Board of Directors, enhancing its leadership team. Dr. Singhvi, possessing over 30 years of biotechnology experience, previously held significant roles at Takeda, Novavax, and Merck. He is recognized for his expertise in drug development and biomanufacturing, currently serving as CEO of National Resilience. His addition is expected to bolster Codexis’ innovative product pipeline and further the company's mission in enzyme engineering and biotherapeutics. This strategic move is anticipated to drive growth and enhance market position.
Codexis, Inc. (NASDAQ: CDXS) hosted its Protein Engineering Forum on September 12-13, 2022, in San Francisco. This event attracted over 100 scientists and innovators to discuss advancements in genomics, nucleic acid synthesis, and synthetic biology. Keynote speaker Dr. Nicholas Turner highlighted innovations in biocatalysts. Attendees from more than 40 organizations exchanged insights, showcasing Codexis' role in facilitating collaboration in protein engineering. The company aims to drive sustainable advancements in pharmaceuticals and industrial products through its enzyme engineering capabilities.
Codexis (NASDAQ: CDXS) announced a strong financial performance for Q2 2022, with total revenue surging 51% to $38.4 million and product revenue rising 135% to $34.6 million, largely driven by sales related to Pfizer’s PAXLOVID™. The company reaffirmed its 2022 revenue guidance of $135M-$141M. Codexis is moving forward with significant partnerships, including a deal with Molecular Assemblies and a $5 million investment in seqWell. Leadership change was also announced, with Dr. Stephen Dilly set to succeed John Nicols as CEO on August 9, 2022.
Codexis (CDXS) and Molecular Assemblies have announced a Commercial License and Enzyme Supply Agreement, allowing Molecular Assemblies to use an advanced terminal deoxynucleotidyl transferase (TdT) enzyme in its Fully Enzymatic Synthesis™ (FES™) technology. This collaboration aims to enhance enzymatic DNA synthesis, producing high-quality oligonucleotides for applications in gene editing, next-generation sequencing, and synthetic biology. The agreement entails milestone payments and royalties, positioning both companies for accelerated commercial success in DNA synthesis.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What does Codexis, Inc. specialize in?
How does Codexis generate revenue?
What industries benefit from Codexis’ products and services?
What is the CodeEvolver® technology platform?
Where does Codexis derive its revenue from geographically?
What recent collaborations has Codexis entered into?
What is the significance of Codexis’ strategic collaborations?
What recent achievements has Codexis made in biotherapeutics?
How does Codexis ensure the quality of its products?
How can I stay updated with Codexis’ latest news and developments?
